Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Apr;17(2):170-6.
doi: 10.1097/MCC.0b013e328344a076.

Acute-on-chronic liver failure: the liver and portal haemodynamics

Affiliations
Review

Acute-on-chronic liver failure: the liver and portal haemodynamics

Rajeshwar P Mookerjee. Curr Opin Crit Care. 2011 Apr.

Abstract

Purpose of review: During acute-on-chronic liver failure (ACLF), the marked systemic inflammatory response and rapid deterioration in liver function are associated with a significant deterioration in organ perfusion and an appreciable rise in portal pressure. Indeed, the development of sepsis and multiorgan dysfunction that commonly follows presentation in these patients is intricately related to the severity of portal hypertension. It follows that understanding the drivers for rising portal pressure in ACLF will inform new therapies.

Recent findings: As this review aims to highlight, there has been a paradigm shift in understanding of the drivers of portal hypertension, from a prior focus on splanchnic vasodilatation and therapies targeting portal inflow, toward appreciation of increasing intrahepatic resistance as the trigger for further vascular derangement, especially in the context of systemic inflammatory responses.

Summary: By elaborating on those mechanisms that are especially perturbed by inflammatory responses, this article aims to show how this understanding has helped inform the identification of potential new targets for therapy in ACLF. Particular emphasis is given to agents with data supporting their progression toward clinical trials and those currently undergoing validation in clinical studies.

PubMed Disclaimer

Publication types

MeSH terms